In a filing, Janux Therapeutics Inc revealed its President and CEO Campbell David Alan unloaded Company’s shares for reported $0.3 million on Jan 07 ’25. In the deal valued at $60.00 per share,5,000 shares were sold. As a result of this transaction, Campbell David Alan now holds 293,054 shares worth roughly $11.99 million.
Then, Campbell David Alan bought 5,000 shares, generating $300,004 in total proceeds.
Before that, Meyer Andrew Hollman sold 13,334 shares. Janux Therapeutics Inc shares valued at $731,785 were divested by the Chief Business Officer at a price of $54.88 per share. As a result of the transaction, Meyer Andrew Hollman now holds 82,139 shares, worth roughly $3.36 million.
H.C. Wainwright reiterated its Janux Therapeutics Inc [JANX] rating to a Buy in a research note published on December 03, 2024; the price target was $70. A number of analysts have revised their coverage, including BTIG Research’s analysts, who remained covering the stock and in early December has reiterated a ‘”a Buy”‘ rating for it. Leerink Partners began covering JANX with “an Outperform” recommendation on November 22, 2024. UBS started covering the stock on October 24, 2024. It rated JANX as “a Buy”.
Price Performance Review of JANX
On Tuesday, Janux Therapeutics Inc [NASDAQ:JANX] saw its stock jump 0.47% to $40.91. Over the last five days, the stock has lost -9.21%. Janux Therapeutics Inc shares have fallen nearly -23.59% since the year began. Nevertheless, the stocks have risen 343.71% over the past one year. While a 52-week high of $71.71 was reached on 01/07/25, a 52-week low of $7.79 was recorded on 01/21/25. SMA at 50 days reached $53.03, while 200 days put it at $47.95.
Levels Of Support And Resistance For JANX Stock
The 24-hour chart illustrates a support level at 39.91, which if violated will result in even more drops to 38.90. On the upside, there is a resistance level at 41.96. A further resistance level may holdings at 43.00. The Relative Strength Index (RSI) on the 14-day chart is 30.25, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -7.73, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.56%. Stochastics %K at 2.61% indicates the stock is a buying.
How much short interest is there in Janux Therapeutics Inc?
A steep rise in short interest was recorded in Janux Therapeutics Inc stocks on 2024-12-31, growing by 3.2 million shares to a total of 7.68 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 4.48 million shares. There was a rise of 41.69%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 06, 2024 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $70 price target.
